Aclaris Therapeutics

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aclaris Therapeutics reports Q1 earnings, highlights ATI-450 trial results

Aclaris Therapeutics reported financial highlights, discussed trial results for ATI-450, and highlighted optimism about its pipeline.
Strengths include targeted PD inhibition in HS study, competitive landscape discussions in atopic dermatitis, and changes in inclusion criteria for studies.
Challenges involve CNS adverse events in HS study, enrollment hurdles in psoriatic arthritis trial, and scrutiny on CK elevations and comparisons to other therapies.
Opportunities lie in potential value creation in immune-inflammatory diseases, market positioning in atopic dermatitis, and patient engagement strategies in RA and PSA studies.

Aclaris Therapeutics progresses ATI-2138 for atopic dermatitis, eyes growth

Aclaris Therapeutics is focused on advancing ATI-2138 for atopic dermatitis with a strong financial position. While facing questions on various fronts, the company's strategic direction and commitment to innovation offer promising opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The biotech has completed enrollment in the next phase of an important development program. It is aiming to get a rheumatoid arthritis drug to market.

Why Aclaris Therapeutics Topped the Market on Tuesday

- Topline Data Anticipated in Q4 2023 WAYNE, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment into ATI-450-RA-202, its Phase 2b trial of oral zunsemetinib in patients with moderate to severe rheumatoid arthritis (RA).

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

WAYNE, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in two healthcare investor conferences in June.

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

Aclaris Therapeutics, Inc. (NASDAQ:ACRS ) Q1 2023 Earnings Conference Call May 8, 2023 8:00 AM ET Company Participants Robert Doody - Head of Investor Relations Douglas Manion - Chief Executive Officer Gail Cawkwell - Senior Key Executive Joseph Monahan - Chief Scientific Officer Kevin Balthaser - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Corinne Jenkins - Goldman Sachs Thomas Smith - SVB Securities Alexander Thompson - Stifel Roger Song - Jefferies Dipesh Patel - Wainwright Julian Harrison - BTIG Lachlan Hanbury-Brown - William Blair & Company Operator Good day and thank you for standing by. Welcome to Aclaris Therapeutics First Quarter 2023 Conference Call.

Aclaris Therapeutics, Inc. (ACRS) Q1 2023 Earnings Call Transcript

- Management to Host Conference Call at 8:00 AM ET Today – WAYNE, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2023 and provided a corporate update.

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

WAYNE, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2023 on Monday, May 8, 2023, before the opening of the U.S. financial markets.

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

Amyris

Ionis Pharma

In a high-interest-rate environment, cash is king. All biotech companies will need to continue spending to finance their R&D.

3 Biotech Stocks to Sell Before They're 6 Feet Under

WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 1:00 PM ET.

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Aclaris Therapeutics reported disappointing marks for zunsemetinib's “ATI-450” Phase IIa trial for moderate to severe hidradenitis suppurativa. The share price has been nearly chopped in half. The trial missed the primary and secondary efficacy endpoints. Aclaris mentioned that the placebo arm outperformed the efficacy observed in other studies.

Aclaris Therapeutics: Potential Speculative Play After Zunsemetinib Misses Mark On Hidradenitis Suppurativa

BridgeBio Pharma Inc

Markets were mixed, with large caps rising as small caps gave up ground. BridgeBio Pharma showed positive trial results for a treatment for a disease that limits growth.

These 2 Biotech Stocks Made Big Monday Moves

Aclaris' phase 2a clinical study of zunsemetinib in treating a chronic skin condition didn't meet its primary or secondary endpoints. The company continues to move forward with other clinical studies for the experimental drug targeting other skin conditions.

Why Aclaris Therapeutics Is Crashing Today

WAYNE, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2022 and provided a corporate update.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

WAYNE, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 9:20 AM ET.

Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference

Aclaris Therapeutics, Inc. stands out with a very interesting pipeline of treatments under development. The company's pipeline of treatments targets specific conditions resulting from autoimmune diseases.

Aclaris Therapeutics Has Strong Upside Potential, But Shares Could Be Lower

WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today is providing a corporate outlook for 2023.

Aclaris Therapeutics Provides 2023 Outlook

WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and Pediatrix Therapeutics, Inc. (Pediatrix), a pediatrics-focused therapeutic company, today announced that the companies have entered into a license agreement. Under the license agreement, Aclaris has granted Pediatrix the exclusive rights to develop, manufacture and commercialize ATI-1777, Aclaris' investigational “soft” Janus kinase (JAK) 1/3 inhibitor, for any disease, including atopic dermatitis, in Greater China (Mainland China, Hong Kong, Macau and Taiwan). Aclaris will retain the rights to develop, manufacture and commercialize ATI-1777 in the rest of the world.

Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China

- Dr. Neal Walker to transition to Chair of the Board of Directors

Aclaris Therapeutics Announces Key Leadership Transitions

WAYNE, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the company will participate in two November healthcare investor conferences.

Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences

Aclaris (ACRS) delivered earnings and revenue surprises of 23.08% and 1,083.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates

- Completed Enrollment in Phase 2a Trial of Zunsemetinib in Hidradenitis Suppurativa; Topline Data Expected in Mid-first Half of 2023

Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has appointed Robert A. Doody Jr. as Vice President, Investor Relations.

Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations

WAYNE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, CEO of Aclaris, will virtually present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, which will be available on-demand beginning on Monday, September 12, 2022 at 7:00 a.m. ET. Management will be available September 12th throughout the day for virtual 1x1 meetings.

Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced a non-exclusive patent license agreement with Eli Lilly and Company (Lilly).

Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata

Aclaris (ACRS) delivered earnings and revenue surprises of 13.89% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue Estimates

WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2022 and provided a corporate update.

News for Aclaris Therapeutics Stock (ACRS)